Nasal spray aims to fight COVID-19, but trial halted early
Disease control
Terminated
This study tested a nasal spray called AD17002 in 180 adults with mild to moderate COVID-19. Participants received either a low dose, high dose, or placebo spray alongside standard care. The goal was to see if the spray speeds up recovery and improves symptoms. However, the trial…
Phase: PHASE2, PHASE3 • Sponsor: Advagene Biopharma Co. Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:12 UTC